


Axxam's integrated approach: a complexity-escalating strategy for bringing NAMs to human-relevant drug discovery

Sonia Viganò*, Alessandro Cinti*, Viviana Agus*, Silvia Cainarca*, JeanFrancois Rolland*
*Axxam S.p.A. OpenZone, Via Meucci 3, 20091 Bresso (Milan), Italy

Many drug candidates fail because efficacy, safety or biodistribution issues are not identified early


Axxam's integrated drug discovery program, named **Discovery^{MAXX}**, enables deeper evaluation at the beginning of the discovery process, reducing the risk of delays, costly setbacks, and late-stage failure, and ensuring programs advance with greater confidence and clarity.



Early de-risking



Data-informed decisions to bridge the translational gap

- Focus on the **disease**
- **Target candidates** supported by multiple layers of evidences
- Anticipate tractability and safety liabilities of **molecule candidates**



- AI-enhanced **clinical relevance** and **toxicity prediction**
- **Advanced iPSC- and 3D models** target validation
- Tailored **MoA and pharmacology** assay
- **Off-target** effects by Counter-screen and Secondary Assays
- **Efficacy & toxicity**: Primary and Secondary/ Orthogonal Assays
- **Primary screening**, Hit confirmation and validation, initial SAR
- **Biodistribution**: Preliminary ADME
- Full Medicinal Chemistry H2L program
- MoA in **advanced, disease-relevant models**
- Biodistribution (Tier I, II, III ADME; *in vivo* PK)
- Off-Targets, **preliminary toxicity**
- **Cardiac safety** panel

In vitro assays and tools for disease modelling



Take-home messages

- **Axxam expertise**: support **discovery process** by employing **integrated approaches** and **late phase derisking**
- **Axxam** interest in NAMs and OoC:
 - **Ready-to-use platforms**
 - **Scalable, high-throughput formats** (e.g., 384w plates)
 - **Robust and validated performance**
 - **Cost-effective solutions, affordable at scale**
 - **Patient-derived models and patient-relevant applications**

AXXAM HARNESS BIOLOGY
EMPOWER DISCOVERY

25TH
ANNIVERSARY

